Has John Jackalone, DPM received payments from drug or device companies?

Yes. Drug and device makers reported $65,572 in general payments to John Jackalone, DPM across 234 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Jackalone, DPM did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Jackalone, DPM come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Jackalone, DPM

Foot Surgery · Bethpage, NYNPI 1174620983

Payments from drug & device makers

What this record shows

This record is dominated by other: $58,400 of the $65,572 with a category attached, or 89.1%. Biolab Sciences, Inc. accounts for 89.1% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2022 at $59,664 and has fallen 99.2% since, to $506 in 2025. Among foot surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$65,572in general payments, 2019–2025

Across 234 payments — averaging $280.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Biolab Sciences, Inc.$58K
Organogenesis Inc.$2K
Smith+Nephew$1K
Medical Device Business Services, Inc.$918
AbbVie$649
Nevro Corp.$193
plus $2K from 23 others

What the payments were for

Speaking & faculty fees$2840%
Travel & lodging$7371%
Food & beverage$6,1519%
Other$58,40089%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Biolab Sciences, Inc.	1	$58,400
Organogenesis Inc.	107	$2,306
Smith+Nephew	49	$1,270
Medical Device Business Services, Inc.	7	$918
AbbVie(2 entities)	28	$649
Nevro Corp.	5	$193
Misonix Inc	2	$180
Mimedx Group, Inc.	3	$180
Averitas Pharma Inc.	2	$149
Treace Medical Concepts, Inc.	1	$146
Paratek Pharmaceuticals, Inc.	2	$145
Lifenet Health	2	$142
Biocomposites Inc	1	$138
KCI USA, Inc.	1	$125
Melinta Therapeutics, LLC	1	$125
Hydrofera LLC	2	$100
Convatec Inc.	2	$88
Integra Lifesciences Corporation	3	$40
Acera Surgical, Inc.	1	$40
Aroa Biosurgery Incorporated	3	$37
Kerecis Limited	2	$31
Orthofix Medical, Inc.	1	$31
Advanced Oxygen Therapy Inc.	2	$28
Imbed Biosciences Inc.	1	$21
Cumberland Pharmaceuticals, Inc.	1	$20
TEI Medical Inc.	1	$18
Stryker	1	$18
Bioventus LLC	1	$17
Amgen	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$65,572 in reported general payments places this provider in the 95th percentile of 294 foot surgery providers in New York.

See all foot surgery providers in New York →

Medicare billing

Part B allowed, 2024

$121,943

Medicare patients

199

Services billed

1,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	17	$88

Paid to pharmacies, not to this prescriber.

Other foot surgery in Bethpage

Ronald GubermanRidgewood$337K
David WongBronx$45K
Berdj StepanianWhite Plains$26K
Lawrence SantiBrooklyn$25K
David GitlinBayside$24K
Rick DelmonteNew York$21K
Corrine RenneFranklin Square$20K
Charles MorelliMamaroneck$18K
Evan BrethBrooklyn$17K
Wayne AxmanAstoria$14K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →